Key Takeaways SLP now expects FY25 revenues of $76M-$80M, down sharply from earlier guidance of $90M-$93M. Biotech market challenges have dampened demand for SLP's services, though software remains resilient. SLP is adopting a functional model to boost efficiency, sales effectiveness and client engagement.Simulations Plus, Inc. (SLP) has announced preliminary revenue results for the third quarter of fiscal 2025 and revised its full-year revenue guidance. The company expects third-quarter revenues to be be ...

Simulations Plus, Inc. (SLP) bolstered its flagship quantitative systems toxicology (QST) platform with the launch of DILIsym 11. This new release advances drug-induced liver injury (DILI) prediction, with cutting-edge features like pediatric representation and an enhanced T-cell model, solidifying Simulations Plus’s commitment to improving drug safety and patient outcomes.DILIsym 11 introduces several powerful enhancements to extend its predictive reach and improve simulation accuracy. The enhanced version ...